India's Generic HIV-Prevention Jab Moves Closer, but Three Hurdles Remain Before You Can Get It

Dr Reddy's Laboratories announced on Monday, November 2, that the US Food and Drug Administration has tentatively approved its generic version of lenacapavir, a twice-yearly injection used to reduce the risk of HIV acquisition. Medical Dialogues reports that Dr Reddy's is the first of the six generic makers licensed by Gilead to get this FDA step. It does not mean the drug can be bought in India.

What the approval means

A tentative approval means the FDA found the product meets its safety, efficacy and quality standards, but it cannot be sold in the US because of patent or exclusivity barriers. Its value is elsewhere: procurement agencies and national regulators can lean on the FDA's assessment. Unitaid's Jessica Burry, quoted by Medical Dialogues, said some countries could fast-track approvals on that basis.

The expected price is about $40 a year in countries where the generic becomes available, according to the Associated Press, which Medical Dialogues converts to roughly ₹3,800 a year. The branded version, Gilead's Yeztugo, costs about $28,000 a year in the US. Dr Reddy's has said first supplies should reach a few low-income countries by the end of 2026, and MSF expects wider generic rollout from 2027.

Hurdle one: final approval in India

On August 11, a CDSCO expert committee recommended waiving the local Phase III trial and bioequivalence requirements for the Dr Reddy's and Emcure versions, citing unmet medical need and approvals in the US, Canada, the UK, the EU and Australia. ThePrint was careful to say this is not final marketing approval, and the companies must still obtain the necessary permissions. The committee also wants a Phase IV efficacy study protocol within three months of authorisation. Emcure says it hopes for approval by the end of the financial year.

One detail is easy to miss. The Third World Network notes that the internationally approved PrEP regimen starts with oral lenacapavir tablets as well as the injection, so both components need to be available for the full regimen to work.

Hurdle two: a place in the public programme

India's National AIDS Control Organisation published technical guidelines for PrEP in 2022, but IndiaSpend reports that PrEP is still sold mainly in the private market at ₹2,200 to ₹3,000 a month, or offered by a handful of non-profits in select cities. Over a year, that is ₹26,400 to ₹36,000, roughly seven to nine times the ₹3,800 a year quoted for the generic injectable. That comparison is only indicative. The ₹3,800 figure is an international price, not an Indian retail price, and ThePrint notes that the eventual Indian price is not yet clear.

MSF South Asia put the stakes plainly in September: an estimated 60,000 people in India acquired HIV last year, and it would be a missed opportunity if Indian-made lenacapavir were exported while people in India continued to have very limited access to PrEP of any kind.

Hurdle three: delivery

Lenacapavir is injected by a health worker twice a year. That suits people who struggle with a daily pill, but it needs clinics, trained staff, testing and follow-up. Regulatory approval, ThePrint points out, is only one part of making a drug accessible.

What to watch

1. Whether CDSCO grants final marketing authorisation, and when. 2. Whether the government announces PrEP of any kind, injectable or oral, in the public programme. 3. What the Indian price turns out to be.

Our analysis

India is a manufacturer, an exporter and a country with its own HIV burden, and these roles can pull in different directions. Sending the first doses abroad is reasonable given global need, but it raises a fair question about the order in which India's own patients are served. The most useful signal will not be another approval headline. It will be a public-programme decision, because that is what turns a low price into access.

For readers: the tentative US FDA decision does not itself establish availability in India. Anyone considering HIV prevention should speak to a doctor or a government-approved HIV service.

Sources:

• Dr Reddy's generic lenacapavir to cost around Rs 3,800 annually (Medical Dialogues)
• Associated Press report on the FDA tentative approval
• Generic lenacapavir moves closer to India with CDSCO waiver (ThePrint)
• CDSCO panel nod for CT, BE waivers (Medical Dialogues, Aug 25)
• Third World Network: committee recommendations and the PrEP regimen
• 4 years after guidelines, India's HIV prevention tool remains a privilege (IndiaSpend)
• MSF South Asia statement, September 4, 2026
• CDSCO eases approval process (MedPath)

*This article is for information and is not medical advice.*